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Unkind, almost abrasive, judgements
regarding the value of prophylaxis
therapy with botulinum neurotoxin
type A (BoNTA; BOTOX) in chronic
headache continue to appear in jour-
nals in this field [1–3]. In view of the
increasingly widespread use of this
new therapeutic opportunity, the con-
troversy is raging. Semantic 
discussion about the interpretation of
frequent new reports assessing
BoNTA’s efficacy, both in open or
double-blind studies [4–10], has cre-
ated factions for and against, both
with proponents of high rank [2, 11].
On the other hand, the interna-
tional medical community is going
through a phase of great expectations
for a therapeutic possibility that
could fill the enormous void in pro-
phylaxis in chronic forms of
headache. In fact, except for topira-
mate, this area presents molecules
discovered on average 25–30 years
ago, with a limited efficacy in time
and often unacceptable side effects.
I believe a remark on the reasons
should be made.
First of all, the treatment of
chronic daily headache (CDH) is still
inadequate. Effective, well tolerated
prevention represents the ultimate
goal for complete rehabilitation of
CDH patients. Medication overuse
headache is often superimposed on
CDH, causing the re-prophylaxis
phase schedule after detoxification to
be inadequate and providing short-
term relief given by the few existing
“old-fashioned” prophylaxis drugs.
The number of patients with CDH,
including all the clinical forms men-
tioned in the definition, is growing.
With respect to chronic tension-type
headache, chronic migraine, trans-
formed migraine, hemicrania contin-
ua and new daily persistent headache,
as the various facets of CDH, the
therapeutic armamentarium is still
based on old drugs: antidepressants
(tricyclics) and non-steroidal anti-
inflammatory drugs (NSAIDs); and
the new entry topiramate. Nothing
more. There is an evident paucity of
EBM-based current treatments used
in CDH prevention. Both topiramate
and BoNTA seem to represent – in
terms of efficacy – the most convinc-
ing options in the operational thera-
peutic scenario of CDH.
Nevertheless, the incidence of
adverse events (AEs) should always
be considered in the therapeutic
choice of these chronic disorders,
which are often complicated with
MOH.
A retrospective analysis of both
open and double-blind studies on the
efficacy of BoNTA in CDH, with or
without MOH, showed conflicting
results. Negative results in such trials
appear to be explained with a bias in
the selection of CDH patients with
MOH.
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BoNTA’s prevention mechanism
for CDH is not completely known,
and probably not only based on neu-
romuscular junction Ach inhibition.
BoNTA may have a distinct antinoci-
ceptive mechanism or inhibition of
CGRP release, SP and other neu-
ropeptides at trigeminal levels, as
suggested by studies on animal mod-
els [12]. Also, scientific evidence on
BoNTA mechanisms of action sup-
ports its efficacy on migraine through
suppressive activity on pain, flare and
hyperalgesia induced by capsaicin
injection in the forehead [13].
Furthermore, it is necessary to
mention a series of pharmacoeconom-
ic analyses, which find the assump-
tion that BoNTA therapy represents a
high-cost alternative compared to tra-
ditional treatments to be untrue.
Recently, an analysis of BoNTA’s
efficacy as a preventive treatment for
chronic tension-type headache (CTTH)
has illustrated its impact on headache
pharmaceutical utilisation and costs.
A retrospective chart review on the
efficacy of BTX-A preventive treat-
ment in a large series of CTTH
patients has been followed by a one-
year prospective analysis of headache
pharmaceutical utilisation and costs
before and after BoNTA treatment. A
direct survey of pharmaceutical con-
sumption per patient has been carried
out with appropriate questionnaires
[14, 15]. Pharmaceutical average costs
and incremented (additional) average
costs criteria were used for the periods
before and after BoNTA treatment.
The retrospective chart review
revealed that BoNTA treatment
resulted in 26% of patients with a
total absence of pain and substantial
reduction in pharmaceutical use; 37%
of patients reported significant pain
reduction and significant reduction in
pharmaceutical use; 22% of patients
reported some pain reduction and a
slight reduction in pharmaceutical
use; and 15% of patients reported no
effect or “possible” worsening of
pain and no reduction in pharmaceu-
tical use [15]. A subsequent one-year
prospective analysis revealed that
after BoNTA treatment there was a
45% reduction in the consumption of
analgesics/antimigraine drugs, a 35%
reduction of NSAIDs and a 100%
reduction of other off-label prophy-
lactic agents. The average costs of
medications had been reduced from
€ 853.43 before BoNTA treatment to
€ 450.47 afterwards [16]. The overall
conclusion of these studies displayed,
together with BoNTA’s efficacy for
CTH, a substantial reduction of
headache medication utilisation and
costs. This completely contradicts the
high-cost hypothesis for this innova-
tive therapy.
We can reasonably affirm that
BoNTA is efficacious, safe and con-
venient, especially in CDH patients
not affected by drug abuse following
the acute treatment of headache itself.
Therefore, from a pragmatic EBM
perspective, we must consider a non-
hostile attitude towards this new
advancing therapeutic opportunity to
be ethically correct, based on the
homogeneous and widespread demand
of an increasing number of patients
[17]. Contrasting information could
produce uncertainty in the headache
scientific body, which reached its cred-
ibility with difficulty that becomes
sometimes still threatened by danger-
ous rifts. A negative attitude should be
avoided, at least until BoNTA’s regis-
tration phase is complete and a final
consensus has been reached.
All these data and considerations
demand that we do not deny our
CDH patients a new pathway, which
seems to lead to an innovative and
efficacious prophylaxis therapy [18].
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